Perform baseline transthoracic echocardiogram, coagulation profile, and basic metabolic panel. Ensure patient has been NPO for 6 hours. Confirm absence of active infection and document informed consent.
Monitor vital signs and puncture site for 2-4 hours. Perform focused physical examination and routine post-procedure assessment. Patient must remain supine for 2 hours post-procedure. Provide discharge instructions regarding activity restrictions and follow-up appointment.
1. Comprehensive Introduction & Overview
The PASCAL Mitral Repair System represents a paradigm shift in the transcatheter management of mitral regurgitation (MR). Developed by Edwards Lifesciences, this technology is engineered to address both degenerative mitral regurgitation (DMR) and functional mitral regurgitation (FMR) in patients who are deemed at high or prohibitive surgical risk.
The PASCAL system utilizes a transcatheter edge-to-edge repair (TEER) approach. By mimicking the surgical "Alfieri stitch," the device approximates the mitral valve leaflets, creating a double-orifice valve that significantly reduces regurgitant volume. Unlike traditional open-heart surgery, which requires sternotomy and cardiopulmonary bypass, the PASCAL system is delivered via the femoral vein, offering a minimally invasive alternative that preserves the native valve architecture while restoring hemodynamic stability.
As the population ages, the prevalence of moderate-to-severe mitral regurgitation continues to rise. The PASCAL system stands as a critical therapeutic intervention for patients suffering from congestive heart failure symptoms who are refractory to guideline-directed medical therapy (GDMT).
2. Deep-Dive: Technical Specifications and Mechanisms
The PASCAL system is defined by its sophisticated design, which balances atraumatic leaflet capture with robust structural stability.
The Device Architecture
The system consists of the PASCAL implant and the steerable catheter delivery system. Key features include:
- Paddles: Two broad, contoured paddles that provide a large surface area for leaflet coaptation. These paddles are designed to distribute tension evenly across the tissue, minimizing the risk of leaflet tear.
- Spacers: A central spacer positioned between the paddles, which acts as a scaffold to fill the regurgitant orifice, further reducing regurgitation beyond simple approximation.
- Independent Leaflet Grasping: The device allows for independent actuation of each paddle, enabling the clinician to capture one leaflet at a time. This is critical in complex anatomy where the anterior and posterior leaflets may not be aligned.
- Steerable Catheter: The delivery system features advanced multi-axis steering, allowing for precise positioning within the left atrium, even in dilated hearts.
Mechanism of Action
- Navigation: The system is introduced via the femoral vein, crosses the atrial septum (transseptal access), and enters the left atrium.
- Alignment: The device is oriented perpendicular to the line of coaptation.
- Grasping: The paddles are opened, and the leaflets are captured using the independent gripper mechanism.
- Assessment: Real-time transesophageal echocardiography (TEE) is used to confirm reduction in MR.
- Release: Once optimal reduction is achieved, the implant is detached from the delivery system.
3. Extensive Clinical Indications & Usage
Indications for Use
The PASCAL system is indicated for patients with:
* Symptomatic Mitral Regurgitation: NYHA Class II, III, or IV symptoms despite optimized medical therapy.
* Anatomical Suitability: Patients with DMR or FMR whose anatomy is conducive to edge-to-edge repair (as determined by a Heart Team).
* Surgical Risk: High or prohibitive risk for traditional surgical mitral valve repair or replacement.
Pre-Operative Preparation
Success with the PASCAL system requires rigorous multidisciplinary planning:
| Step | Action |
|---|---|
| Imaging | Comprehensive TEE to assess leaflet length, coaptation depth, and regurgitant jet location. |
| Heart Team Review | Consensus between interventional cardiologists, cardiac surgeons, and imaging specialists. |
| Medical Optimization | Titration of GDMT (ACE inhibitors, beta-blockers, diuretics) to stabilize hemodynamics. |
| Vascular Access Assessment | CT angiography to ensure femoral vein patency and size for large-bore access. |
4. Procedure Steps: The Interventional Workflow
The procedure is typically performed under general anesthesia with continuous TEE guidance.
- Transseptal Puncture: The clinician performs a transseptal puncture, targeting a high and posterior position in the fossa ovalis to facilitate optimal maneuvering in the left atrium.
- Device Positioning: The catheter is advanced into the left atrium. The delivery system is flexed to align the PASCAL device with the mitral valve orifice.
- Leaflet Capture: The independent grippers are deployed. The posterior leaflet is usually captured first, followed by the anterior leaflet.
- Evaluation: Before final release, the team evaluates the reduction of MR, the mean mitral valve gradient, and the presence of any residual regurgitant jets.
- Implant Release: If the reduction is satisfactory and the gradient is acceptable (<5 mmHg), the device is detached.
- Hemostasis: The large-bore femoral access site is closed using suture-based closure devices.
5. Post-Operative Recovery and Outcomes
Post-Op Protocol
- Immediate: Monitoring in the ICU or cardiac step-down unit for 24 hours.
- Anticoagulation: Typically, dual antiplatelet therapy (DAPT) is prescribed for the first 1–6 months, followed by lifelong single antiplatelet therapy, unless otherwise indicated (e.g., atrial fibrillation).
- Activity: Progressive mobilization starting on post-operative day 1.
Typical Outcomes
- Symptom Relief: Significant improvement in NYHA functional class within 30 days.
- Hemodynamic Improvement: Reduction in left ventricular end-diastolic volume over time due to reverse remodeling.
- Quality of Life: Enhanced 6-minute walk test performance and reduced hospitalization rates for heart failure.
6. Risks, Side Effects, and Contraindications
Potential Complications
- Vascular Injury: Hematoma or pseudoaneurysm at the femoral access site.
- Device-Related: Leaflet detachment, device embolization, or thrombus formation on the implant.
- Cardiac: Pericardial effusion, cardiac tamponade, or iatrogenic atrial septal defect (ASD).
- Procedural: Need for conversion to open-heart surgery.
Contraindications
- Inability to tolerate procedural anticoagulation.
- Active endocarditis.
- Anatomy unsuitable for TEER (e.g., severe mitral stenosis or extremely short leaflets).
- Evidence of intracardiac thrombus.
7. Alternative Treatments
Patients who are not candidates for PASCAL may be considered for:
* Surgical Mitral Valve Repair/Replacement: The gold standard for low-risk patients.
* Transcatheter Mitral Valve Replacement (TMVR): Using devices like the Tendyne or Intrepid for patients with anatomy not suitable for edge-to-edge repair.
* Medical Management (GDMT): For patients who are not candidates for any structural intervention.
8. Massive FAQ Section: Addressing Common Clinical Queries
1. How does PASCAL differ from MitraClip?
While both are TEER devices, PASCAL offers independent leaflet grasping and a central spacer, which may provide more flexibility in complex anatomical cases.
2. Can the PASCAL device be retrieved?
Yes, the device is fully recapturable and repositionable until the final release step.
3. What is the typical procedure duration?
The procedure usually lasts between 90 and 150 minutes, depending on the complexity of the valve anatomy.
4. How long does the patient stay in the hospital?
Most patients are discharged within 24–48 hours post-procedure.
5. Will the patient need blood thinners for life?
Usually, DAPT is required for a few months, but lifelong anticoagulation is only necessary if there are comorbid conditions like atrial fibrillation.
6. Is the PASCAL system MRI safe?
Yes, the PASCAL implant is considered MR-conditional. Always consult the specific device manual for current scan parameters.
7. What is the "Mean Mitral Gradient" and why does it matter?
The gradient measures the resistance to blood flow through the valve. A high gradient post-procedure indicates potential mitral stenosis caused by the device; therefore, maintaining a low gradient is a primary goal.
8. Can PASCAL be used in patients with prior mitral surgery?
It may be considered on a case-by-case basis, depending on the type of prior repair or the presence of prosthetic rings.
9. What if the patient has a very large regurgitant orifice?
Multiple PASCAL devices can be implanted to ensure adequate coaptation and complete reduction of the MR jet.
10. How does the Heart Team decide on the therapy?
The Heart Team uses a combination of TEE imaging, surgical risk scores (STS score), and clinical assessment to determine if the patient's anatomy is better suited for PASCAL versus open surgery or other transcatheter options.
Conclusion
The PASCAL Mitral Repair System is a sophisticated, evidence-based solution for patients suffering from severe mitral regurgitation who are high-risk surgical candidates. By combining precise mechanical control with a user-friendly delivery system, it provides a durable, minimally invasive pathway to improved cardiac function and superior patient quality of life. As clinical experience grows, the role of PASCAL in the standard of care for structural heart disease continues to solidify, offering hope to those who were previously considered untreatable.